Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-85
SponsorChinese University of Hong Kong
About this trial
The study is to attain early recognition of the unstable plaques which have an imminent embolic risk in patients with intracranial atherosclerotic disease (IAD).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient is 30 to 85 years of age, inclusive.
Patients who have an acute infarct in diffusion-weighted MRI compatible with artery-to-artery thrombo-embolism, a relevant intracranial atherosclerotic stenosis ≥60%, and MES detected by TCD.
Patient who has no contra-indication for the proposed imaging tests.
Patient understands the purpose and requirements of the study, and has provided an informed consent.
Disqualifiers
Stroke etiology uncertain or unrelated to intracranial atherosclerosis, such as cardioembolism, Moyamoya disease, small vessel disease, etc.
A tandem stenosis >50% at proximal internal carotid artery.
Bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets <100 x 109/L), coagulopathy (INR >1.5).
A medical condition that would not allow the patient to adhere to the protocol or complete the study.
Trial population
Patients who admitted to Prince of Wales Hospital for acute stroke will be screened for eligibility.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
DSA/3DRA
Diagnostic testDSA/3DRA
Treatment groups
140 Participants
are divided into 2 treatment groupsGroup A: Symptomatic stroke patient1 intervention
Group B: Asymptomatic stroke patient1 intervention
Trial outcomes
Primary outcomes
1
The plaque morphology of high-risk IAD may be distinct from the silent ones.
The morphological attributes (surface outline, angulations and plaque volume) and collateral grading will be compared between symptomatic and asymptomatic group.
Time frame
Dec, 2020Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov